To investigate the expression levels of S100A4 in human colorectal carcinoma (CC) and its relationship with clinicopathological parameters and metastatic potential, 73 pathological specimens from patients with CC were examined for S100A4 expression by RT-PCR and immunohistochemistry. An increase of S100A4 mRNA was observed in 19/23 (82.6%) CC specimens, and S100A4 was up-regulated in 40/73 (54.7%) CC cases compared with non-neoplastic mucosal tissues. Upregulation of S100A4 was significantly related to invasion, nodal status, distant metastasis and p53 expression. Next, we investigated whether S100A4 could affect p53 transactivation and stability. Interestingly, it was revealed that treatment with exogenous S100A4 protein reduced transcriptional activity of p53 and abrogated the modification of calcium binding affinity of S100A4 protein. These findings suggested that S100A4 might be involved in the progression and metastasis of human CC, presumably via modulation of the wild-type p53 protein.
Introduction
Human colorectal carcinoma (CC) is one of the major causes of morbidity and mortality worldwide (1) . Its tumorigenic mechanism is a multi-step process related to the genetic instability associated with genetic alterations (2) (3) (4) . Currently, there are a few immunohistochemically detectable markers relevant of colorectal carcinoma (5) . Of these tumor markers, S100A4 protein has been shown to be associated with progression and worse prognosis of human colorectal cancer (6) (7) (8) .
S100A4 protein belongs to the S100 subfamily of a calcium binding protein (also called mts 1, p9Ka, CAPL, and calvasculin) (9, 10) . It is characterized by the EF-hand structural motif and consists of 101 amino acids. It is activated by Ca 2+ binding to the two EF-hand motifs, which induces a conformational alteration and homodimerization, resulting in exposure of binding sites for the target protein.
Non-muscle tropomyosin (11) , non-muscle myosin (12) , Liprin beta 1 (13) , and p53 (14, 15) are well known target proteins of S100A4. Through interactions with these target proteins, it is believed that S100A4 is involved in cytoskeletal dynamics, cell motility and cell growth. Previous studies have shown that S100A4 protein is overexpressed in various human cancers such as malignant gastrointestinal cancer (6, 8, (16) (17) (18) , breast cancer (19, 20) , and non-small cell lung cancer (21) , and that this overexpression may influence a patient's clinical prognosis.
To confirm the functional and clinicopathological roles of S100A4 in tumorigenesis of human CC, we analyzed the possible correlation between S100A4 expression and clinocopathological prognostic parameters in 73 human CCs. We also investigated the intracellular biological role of S100A4 in the regulation of p53 transactivation and stability.
Materials and methods

Patient samples and cell lines.
The human CC samples were obtained from patients who underwent routine surgery for colorectal cancer at the Department of Surgery, Eulji University Hospital. For immunohistochemical analysis, the 73 colorectal carcinoma tissues were paired with normal mucosal tissue taken from a site distant from the tumorous lesion. Tissues were then fixed in 10% neutralized buffered formalin solution for 24 h. Some tissue specimens were immediately frozen after resection and stored in liquid nitrogen (22) . All cell lines used in our studies were purchased from American Type Culture Collection (ATCC, Rockville, MD). The human colon adenocarcinoma cell line, HCT116, and the p53-null human cancer cell line, H1299 were used. These cells were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum (Gibco BRL, Grand Island, NY) and 1% antibiotic-antimycotic solution (Gibco BRL) and kept at 37˚ in a humidified incubator maintained with 5% CO 2 .
Reverse transcription-polymerase chain reaction (RT-PCR)
analysis. Total RNA was extracted from 23 samples out of 73 colorectal carcinoma and non-tumorous tissues from patients using the AGPC method (23) . Extracted RNA was reverse-transcribed using a cDNA synthesis kit (Stratagene, La Jolla, CA) following the instruction manual. cDNA was synthesized using 5 μg of total RNA and oligo (dT) primer in 50 μl of a solution containing reverse transcriptase. The reverse-transcribed samples were used to amplify the 280 bp fragment of S100A4 by PCR. GAPDH was used as an internal quantitative control. The PCR primer sequences of S100A4 were as follows: 5'-CGGGATCCATGGCGTGCC CTCTGGAG-3' and antisense primer 5'-CCGCTCGAGTCA TTTCTTCCTGGGCTG-3'. GAPDH primer sequences were as follows: sense primer 5'-CCCCTGGCCAAGGTCATC CATGACAACTTT-3' and antisense primer 5'-GGCCAT GAGGTCCACCACCCTGTTGCTGTA-3'. PCR reactions were performed using a Minicycler™ PCR system (MJ Research, Inc.) using the following cycling parameters: 10 min at 94˚C followed by 25 cycles of 1 min at 94˚C, 1 min at 55˚C, and 1 min at 72˚C, and a final cycle at 72˚C for 10 min. Quantitation of PCR products was performed using a Quantity One program (Bio-Rad, Hercules, CA).
Immunohistochemical analysis.
Immunohistochemistry was performed to study altered S100A4 expression in 73 human colorectal carcinoma tissues. Mouse monoclonal antibodies against S100A4 (KRIBB) and p53 DO-7 (Dako, Glostrup, Denmark) were used as primary antibodies. In brief, paraffin sections of colorectal carcinoma tissue from patients were deparaffinized with xylene and rehydrated. Antigenic retrieval was performed by submerging slides in citrate buffer (pH 6.0) and microwaving. The sections were then treated with 3% hydrogen peroxide in methanol to quench the endogenous peroxidase activity, followed by incubation with 1% BSA to block the non-specific binding. Primary monoclonal anti-S100A4 and p53 antibodies (1:100) were added to the sections and incubated for 60 min at room temperature. After washing, biotinylated anti-mouse secondary antibody was added to sections, followed by incubation with streptavidinhorseradish-peroxidase complex. The tissue sections were immersed in 3-amino-9-ethyl carbazole (AEC) as a substrate, and counterstained with 10% Mayer's hematoxylin, dehydrated, and mounted with crystal mount. Non-immune mouse IgG of the same isotype and dilution was used for negative controls. The degree of immunostaining of the formalinfixed, paraffin-embedded sections was evaluated by two independent observers, and moderate to strong cytoplasmic or nuclear staining was considered as a positive reaction. The distribution of S100A4 was scored on a semiquantitative scale as follows: negative/focal (<20% of the cells were positive), moderate (small cell clusters, but 20-70% of the cells were positive) and diffuse (>70% of the cells were positive). (B) Expression levels displayed as the ratio between the signal strength of S100A4 and a reference gene (GAPDH) to compensate for the variation in the amounts of RNA. The expression of S100A4 gene was increased in CC when compared with corresponding normal mucosa.
Construction of S100A4 mutants deficient in calcium binding and dimerization and luciferase assay.
Wild-type p53 expression vector and pRGC 17 -luciferase reporter gene were a gift from Oren Moshe (Weizmann Institute of Science). Expression plasmids encoding the nucleotide sequence corresponding to the full open reading frame (ORF) for S100A4 were subcloned as 5' BamHI/3' XhoI fragment into pcDNA3.1 (+) (Invitrogen) for transfection. To further evaluate the roles of calcium binding and dimerization in S100A4 in the interaction between the S100A4 and p53 protein, we developed a set of S100A4 mutant constructs deficient in calcium binding and dimerization sites, as reported by Kim et al (24) . HCT116 cells were plated at 2x10 5 cells/well on a 6 well plate. After 24 h the cells were transfected with various combinations of plasmids encoding luciferase under control of the p53 promoter (0.5 μg) and wild-type p53 (1 μg) with or without a fragment of S100A4 (1 μg) and pcDNA3.1 (+) empty vector using the Fugene 6 reagent (Boehringer Mannheim) as recommended by the manufacturer. A ß-galactocidase-expressing vector was included as an internal control for transfection efficiency. For transient transfections, cells were collected after 24 and 48 h. Luciferase assays were performed using a commercial luciferase assay system (Promega, Madison, MI), employing an LB9501 luminometer (Berthold Life sciences, Australia). Results are presented as the average of at least three independent experiments.
Immunoprecipitation and immunoblot analyses. Cell lysis, immunoprecipitation, and washing steps were carried out with the buffer (50 mM Tris, pH 7.5, 150 mM NaCl, 0.5% Nonidet P-40, 5 mM EDTA, 1 mM PMSF) at 4˚C. Cell extracts were precleared on protein G-agarose suspension (Roche Molecular Biochemicals) and the supernatant was immunoprecipitated using the S100A4 antibody. Immunoprecipitated proteins were collected on protein G-agarose, washed, eluted in gel loading buffer, and separated by SDS-PAGE. Proteins were transferred to an Immobilon-P (Milipore) ONCOLOGY REPORTS 22: 41-47, 2009 Figure 2. Immunohistochemical staining of S100A4 protein in human CC. (A) S100A4 expression is increased in the CC region compared with that of its adjacent normal mucosal epithelial cells (original magnification, x100). (B) S100A4 protein is distributed throughout the cytosol (magnification, x400). NM, normal mucosa; CC, colorectal carcinoma. Figure 3 . S100A4 inhibits p53 transactivation in human colorectal carcinoma cells, HCT116. (A) Reporter plasmids were co-transfected with various combinations of expression plamids of pcDNA, pcDNA-wild-type p53 and pcDNA-S100A4 in cells. Reporter assay was carried out in triplicate at 24 and 48 h after transfection. The reporter activity was significantly enhanced by introduction of the wild-type p53. This enhanced activity was reduced by the addition of S100A4 to these cells ( * , ** P<0.001). (B) Mutant S100A4 with defective dimerization or calcium binding status did not affect p53 transactivation. Reporter plasmids were co-transfected with various combinations of expression plamids of pcDNA, pcDNA-wild type p53 and pcDNA-mutant S100A4 deficient in dimerization or calcium binding properties. Reporter assay was carried out in triplicate at 24 h after transfection. (membrane and then probed with the primary antibody p53 Ab-6 (Oncogene Science, La Jolla, CA). The blot was analyzed by standard Western blotting procedure with an enhanced chemiluminescence detection system (ECL kit; Amersham, Arlington Heights, IL).
Statistical analysis.
The relationship between the results of the immunohistochemical study and the clinicopathological parameters was determined using the SAS ® software package (version 8.01; SAS Institute, Cary, NC). Univariate and multivariate analyses were carried out using the Proc logistic module. Probability values (P<0.05) were considered to be statistically significant.
Results
S100A4 expression in human colorectal carcinoma.
Expression patterns of S100A4 in human colorectal carcinomas were examined through RT-PCR and immunohistochemical analysis. The relative levels of expression of S100A4 in 23 colorectal carcinoma tissues were compared with those of non-tumorous tissues by RT-PCR. The Table I . Relationship between S100A4 expression and clinicoparameters in human colorectal carcinoma. 
-----------------------------------------------------------------------------------------------------S100A4 expression Negative Lower positive Higher positive P-value -----------------------------------------------------------------------------------------------------
(12%) -----------------------------------------------------------------------------------------------------
a NS, non-significant.
-----------------------------------------------------------------------------------------------------
expression levels were expressed as a ratio between S100A4 and the reference gene (GAPDH) to correct for variation in the amounts of mRNA. The S100A4 mRNA level was significantly increased (P<0.0001) in all of the examined human colorectal carcinomas when compared to its corresponding normal mucosal tissue (Fig. 1) . Increased expression of S100A4 mRNA in tumor tissue was defined as at least 2-3 times higher than that seen in normal colonic mucosal tissue. Immunohistochemical examination of the tumor tissues using monoclonal antibody specific to S100A4 showed that 40 of 73 (55%) colorectal tumor tissues samples had increased levels of S100A4. Normal colorectal mucosa from patients shows negative or weak S100A4 staining in the mucosal epithelial cells. We found that levels of S100A4 were significantly higher in colorectal carcinomas compared to normal mucosal tissue from cancer patients (Fig. 2) , and that S100A4 was mostly localized in the cytoplasm but was also seen in nuclear areas of tumor cells. The expression levels of S100A4 in colorectal carcinoma samples revealed negative/focal, moderately and diffuse positive immunoreactivity in 33, 31 and 9 cases, respectively (data not shown).
Relationship between S100A4 expression and clinicopathological parameters in human colorectal carcinoma. We investigated the expression level of S100A4 and various clinicopathological parameters in colorectal carcinomas to determine whether there is a relationship between the two. There was significant correlation between expression of S100A4 and clinicopathological parameters, such as depth of invasion (P=0.004), distant metastasis (P=0.0069), nodal status (P=0.0017) and p53 overexpression (P=0.07) in univariate analysis (Table I) . Also, multivariate analysis using data from all parameters confirmed that S100A4 expression, depth of invasion, metastasis and p53 overexpression were significant co-variates (P<0.01) (Table II) . S100A4 down-regulates p53 transcriptional activities and stability. To assess the biological role of S100A4, we investigated whether S100A4 affects the transcriptional activity of tumor suppressor p53 using a reporter assay. The intracellular role of S100A4 in transcriptional activity of the wild-type p53 was investigated by co-transfection of various combinations of expression vectors with S100A4 containing a full ORF length and reporter gene with a luciferase tagged p53 promoter in H1299 cell line, which is an S100A4-and p53-negative cell line (Fig. 3) . The value of significantly inhibited transactivity with co-transfection of S100A4 was tested using a luciferase activity assay and analyzed by t-test. Co-transfection assay revealed that transcriptional activity of the wild-type p53 in the presence of S100A4 was suppressed in H1299 cells (P<0.0001, Fig. 3A) . Luciferase reporter gene assay showed that S100A4 mutants that are defective in either their ability to dimerize or in calcium binding were unable to interact with wild-type p53 (Fig. 3B) .
To confirm these results, we performed co-transfection of the S100A4 and p53 protein expression vectors in H1299 cells, Western blot analysis and MTS assay (Fig. 4) . Western blot analysis showed that the protein levels of p53 decreased following co-transfection with S100A4 protein.
Discussion
The S100 proteins belong to a superfamily of proteins containing an EF-hand Ca 2+ -binding mortif. Of these, several S100 proteins such as S100A1, S100A4, S100A5, and S100A6 are found in human colon tissues. Involvement of S100A4 and S100A6 has been proposed to play important biologic roles in tumor progression and metastasis of human colorectal cancer (7) . Human colorectal adenocarcinoma is one of the most common malignancies in the world and the prognosis of patients with this disease has not changed over the last several decades (1-3) . Therefore, it is important to identify any potential tumor marker that is associated with pathophysiologic processes of colorectal carcinoma. S100A4 gene has been isolated as a gene specifically expressed in murine and human metastatic tumor cells (9) . Expression of S100A4 in human colorectal cancer has been correlated with poor prognosis, however, little is known about the intracellular role of S100A4 in the pathophysiologic process of tumorigenesis and metastasis of human colorectal carcinoma. Of the known target proteins that interact with S100A4, p53 is a tumor suppressor protein and a transcriptional factor involved in cell cycle regulation and apoptosis. Grigorian et al have demonstrated that S100A4 binds to the C-terminal regulatory domain of tumor suppressor p53 Table II . Multivariate logistic regression analysis with S100A4 expression. Figure 4 . The induction of exogenous S100A4 destabilizes wild-type p53 in H1299 (p53-null) cells. Cells were co-transfected with p53 (wild-type) and a full fragment of S100A4 and then further incubated for 24 or 48 h before harvesting. p53 was immunoprecipitated with an anti-p53 antibody and analyzed by SDS-PAGE and Western blot analyses using p53 antibody. ·-tubulin was used as a loading control.
protein and enhances p53 dependent apoptosis in human osteosarcoma cell lines (15) . Herein, we confirmed a physical interaction between S100A4 and p53 in the human colon adeno-carcinoma cell lines HCT116 and KM12 with wildtype 53 and mutant-type p53, respectively. As previously described by Chen et al, a physical binding between S100A4 and p53 in tumor cells is likely to occur in part independently of its mutational status (14) . Furthermore, we demonstrate that S100A4 alters p53 function via protein-protein interaction and negatively modulates the transcriptional function of the wild-type p53. We also found that the calcium binding and dimerization status of S100A4 is critical in the interaction between S100A4 and p53 protein.
Taken together, these findings suggest that S100A4 regulates p53-dependent survival of tumor cells in the colorectal adenocarcinoma.
In the present study, we examined the level of S100A4 gene products using RT-PCR in 23 matched colon cancer and adjacent normal colon samples. The results showed that nearly all colorectal carcinoma samples overexpressed S100A4 at the mRNA level. Immunohistochemical staining showed that 55% of colorectal carcinoma samples overexpressed S100A4 protein, which was largely detected in the tumor cells. Additionally, increased expression levels of S100A4 correlated significantly with tumor invasion and metastases in univariate and multivariate analyses. Interestingly, S100A4 overexpression correlated with p53 positive immunohistostaining in human colorectal cancer. The positive immunohistostaining indicates that p53 is mutated in these cases, since the level of wild-type p53 is at or below the level of detection in paraffin-embedded tissue samples. In the present study, the presence of S100A4 strongly down-regulates the wild-type p53 protein in cotransfection luciferase assay. Univariate and multivariate analyses revealed that inceased S100A4 expession significantly correlates with p53 overexpression. Some studies have demonstrated that mutant p53 regulates the expression and promoter activity of endogenous genes, such as c-myc (25) , EGFR (26, 27) , PCNA (28), MDR-1 (29) , causing an increase in oncogenic activities. Taken together, we propose that elevated S100A4 protein expression may promote positive selection of the more malignant phenotype in the early process of tumorigenesis via modulating the wild-type p53-regulated proteins, resulting in aggressive and metastatic clonal expansion regulated by mutant p53 in the more advanced progression of human colorectal carcinoma. However, further investigations are needed to reveal the pathological importance of S100A4 in human colorectal carcinoma.
In conclusion, the present study suggests that alteration of S100A4 can function, at least in part, as a regulator of p53 protein in the development and progression of colorectal carcinoma. Also, S100A4 may be a powerful prognostic marker for human colorectal carcinoma.
